Advertisement

Pharmacist Moms Group

Videos
View More
Expert: How Federal Vaccine Updates Affect Clinicians and Pharmacy Teams

Changes to the federal childhood vaccine schedule have created confusion and variation in practice, placing added responsibility on clinicians and pharmacists to educate patients and ensure evidence-based care.

American Heart Month: How Pharmacists Can Strengthen Cardiovascular Prevention Efforts

During American Heart Month, Sarah Nelson, PharmD, highlights how pharmacists can leverage frequent patient interactions, risk assessment tools, and medication optimization strategies to reduce cardiovascular risk.

Improving Tolerability and Quality of Life in Pancreatic Cancer Treatment with Atebimetinib

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for pancreatic cancer patients.

Expert: Debunking Cholesterol Myths and the Rise of Oral PCSK9 Inhibitors

Joseph Saseen, PharmD, explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

Pharmacist-Led Strategies for Early Tardive Dyskinesia Detection, Patient Support, and Collaborative Care

In this episode, the panel reflects on how this program can help pharmacists strengthen their approach to tardive dyskinesia (TD) recognition and management.

Monitoring and Managing Adverse Events in Hemophilia Prophylaxis

Explore effective strategies for managing side effects in patients, emphasizing communication, monitoring, and education for optimal health outcomes.

Strategies for Supporting Patient Adherence and Effective Communication in Tardive Dyskinesia

In this episode, the panel discusses how pharmacists and the broader care team can support adherence and strengthen communication when patients start deutetrabenazine or valbenazine.

Real-World Insights and Monitoring of Non-Factor Therapies in Hemophilia

Explore the real-world challenges and strategies for patient adherence in treatment, emphasizing education and shared decision-making for better outcomes.

Expert: Early Phase 1 Data Show KTX-1001 Targeting NSD2 Offers Promise for Relapsed/Refractory Multiple Myeloma

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Advertisement
Advertisement

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy